INVO Fertility completes acquisition of Family Beginnings P.C. for $760K, issues preferred stock at premium

summarizeSummary

INVO Fertility, Inc. announced the completion of its acquisition of Family Beginnings P.C. for $760,000, funded by cash and $400,000 in Series D Preferred Stock convertible at a premium to the current share price.

check_boxKey Events

• Acquisition Completed

  INVO Fertility, through its subsidiary Wood Violet Fertility LLC, finalized the acquisition of Family Beginnings P.C., an Indiana-based fertility clinic, for a combined purchase price of $760,000.

• Financing Details

  The acquisition was financed with $360,000 in cash (net $210,000 after a $150,000 holdback) and $400,000 paid in 400 shares of Series D Non-Voting Convertible Preferred Stock.

• Preferred Stock Terms

  The Series D Preferred Stock has a stated value of $1,000 per share and is convertible into common stock at an initial price of $1.20 per share, which is a premium to the current market price of $0.8901.

• Strategic Growth

  The acquired clinic generated approximately $1 million in revenue and $0.2 million in net income for the nine months ended September 30, 2025, representing about 18% of INVO's clinic revenue for the same period, significantly expanding the company's footprint.

auto_awesomeAnalysis

This 8-K filing marks a significant strategic milestone for INVO Fertility, completing a substantial acquisition that immediately expands its operational footprint and revenue base. The acquisition of Family Beginnings P.C. for $760,000 represents a material investment relative to INVO's market capitalization, indicating a strong commitment to growth through M&A. The financing structure, involving Series D Preferred Stock convertible at a premium to the current stock price, suggests institutional confidence in the company's future valuation, despite the potential for future dilution upon conversion. The acquired clinic's historical revenue contribution further underscores the immediate impact on INVO's financial profile. Investors should view this as a positive step in the company's stated strategy to expand access to fertility care.